טוען...

Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147

In the randomized phase III trial N0147 for resected colon cancer, the early trial versions included treatment arms of FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) with and without cetuximab, in addition to FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin) with and without cetuximab. In t...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Huang, Jocelin, Nair, Suresh G., Mahoney, Michelle R., Nelson, Garth D., Shields, Anthony F., Chan, Emily, Goldberg, Richard M., Gill, Sharlene, Kahlenberg, Morton S., Quesenberry, James T., Thibodeau, Stephen N., Smyrk, Thomas C., Grothey, Axel, Sinicrope, Frank A., Webb, Thomas A., Farr, Gist H., Pockaj, Barbara A., Berenberg, Jeffrey L., Mooney, Margaret, Sargent, Daniel J., Alberts, Steven R.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2013
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4019685/
https://ncbi.nlm.nih.gov/pubmed/24512953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clcc.2013.12.002
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!